Targeted SBIR opportunity Leverage ScitoVation’s recent $2.04M Phase II SBIR award from NIEHS to approach clients pursuing regulatory submissions or early-stage clinical programs that could benefit from PBPK modeling and toxicity prediction to support funding and risk assessment.

PBPK modeling leadership Position ScitoVation as the go-to partner for advanced PBPK workflow development and interpretation, offering customized cell-based assays and genetic data analysis to strengthen safety assessments for pharmaceuticals, agrochemicals, and consumer products.

NAMs expertise Highlight NAMs reporting and computational toxicology strengths to attract clients seeking modern, humane, and regulatory-aligned testing strategies that reduce animal testing while delivering actionable toxicity insights.

strategic collaborations Capitalize on ScitoVation’s emphasis on partnerships and flexibility to pursue long-term CRO engagements with mid-market biotech and specialty chemical companies needing scalable safety evaluation and disposition modeling.

leadership & credibility Promote the experienced leadership team and pioneering status in chemical safety to win confidence with potential clients in biotech, food ingredients, and consumer products seeking expert risk assessment and regulatory-ready data.